351 results about "Triple-negative breast cancer" patented technology

The present disclosure relates to a fusion nano liposome-fluorescence labeled nucleic acid in which a bead having a surface binding with a branch-shaped nucleic acid structure labeled with a fluorophore or a branch-shaped nucleic acid structure having a hairpin loop end is included in an inside of a liposome, and a diagnosis application thereof. The fusion nano liposome-fluorescence labeled nucleic acid, or fusion nano liposome-fluorescence labeled hairpin loop structured nucleic acid may sense an external or internal signal, and high-sensitive diagnosis is possible even when mRNA and miRNA which is present at a low concentration in cells being targeted. Further, various target materials expressed inside and outside of a cell membrane may be targeted, and thus even a type of cancer which is hard to diagnose such as triple negative breast cancer also be flexibly diagnosed. Further, using various fluorophores, multiple cancer may be diagnosed at the same time.

The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer.

The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention belongs to the field of medicine and biotechnology, and relates to a synergistic drug compound for treating tumors and a preparation method thereof. The drug compound is composed of one or more cell autophagy inhibitors and arginase, especially human recombinant Arginase is made into a synergistic drug compound for treating tumors, and the synergistic drug compound can inhibit autophagy by inhibiting autophagy through autophagy inhibitors to increase tumor cells' ability to arginase. sensitivity, and enhance the therapeutic effect of arginase, especially human recombinant arginase, on tumors, especially triple-negative breast cancer cells. The drug compound of the present invention can be used for clinical treatment of breast cancer, melanoma, lung cancer, brain tumor, lymphoma, leukemia and myeloma.

The present invention provides methods of detecting triple negative breast cancer recurrence using biomarkers.

The present invention relates to a triple-negative breast cancer marker and applications of the triple-negative breast cancer marker in diagnosis and therapy, and particularly provides uses of a protein C receptor (Procr protein) in preparation of diagnosis reagents or kits for triple-negative breast cancer detection. The research results show that the Procr is the characteristic triple-negative breast cancer marker, such that the Procr can be adopted as the triple-negative breast cancer diagnosis marker. The present invention further provides a method and a pharmaceutical composition for triple-negative breast cancer therapy based on Procr.

The invention discloses a method for screening specific circular RNA (ribonucleic acid) of triple-negative breast cancer. The method includes comparing circular gene expression of triple-negative breast cancer plasma samples and normal comparison groups by the aid of 70 parts of specific circular RNA of breast cancer; screening the specific circular RNA to obtain the circular RNA with functions of specifically obviously expressing the triple-negative breast cancer. The specific circular RNA is used as primers. The method has the advantage that results obtained by the aid of the method have important significance on triple-negative breast cancer diagnosis and treatment.

The present invention relates to biomarkers that are useful in the prognosis of triple negative breast cancer patients. The biomarkers may be used to select treatment and to determine whether a treatment is effective or not. The biomarkers may also be used to select novel treatments and to screen for new potential compounds that may treat the triple negative breast cancer.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The invention relates to a glaucocalyxin derivative, and pharmaceutically acceptable salt dosage forms thereof. A pharmaceutically acceptable salt of the glaucocalyxin derivative is taken as a main material; and dosage forms, comprising one or a plurality of forms selected from injection, solid preparation, external preparation, suppository, and aerosol preparation, are prepared from the pharmaceutically acceptable salt of the glaucocalyxin derivative and a plurality of additives. The glaucocalyxin derivative and the pharmaceutically acceptable salt dosage forms thereof possess excellent water solubility; and oral administration bioavailability is excellent when the glaucocalyxin derivative and the pharmaceutically acceptable salt dosage forms are applied to the field of medicine. The glaucocalyxin derivative and the pharmaceutically acceptable salt dosage forms thereof can be applied to the field of anti-autoimmune disease drug and antitumor drug exploitation, and drug blank of systemic lupus erythematosus, psoriasis, and triple negative breast cancer can be filled.

The present invention provides (1) an agent for the prevention or treatment of an estrogen receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (2) an agent for the prevention or treatment of an estrogen receptor-negative, progesterone receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (3) a method of screening an agent for the prevention or treatment of a breast cancer which is negative for hormone receptors such as an estrogen receptor, a progesterone receptor, etc. and is negative for HER2, which comprises using an Akt inhibitory activity as an indicator; and so on.

The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and / or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The present invention provides a human triple-negative breast cancer cell line designated DKAT. The DKAT cell line has a marker profile of high expression of Snail-1 and Snail-2 (Slug); and a p53 mutation in exon 8 at codon 273 (CGT>CAT). The present invention further provides methods of using the DKAT cell line.

The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer. Likewise, in another example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANG, DICER1, EIF1, and MSH6. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of metastasis of TN breast cancer.

The invention discloses a method for screening specific serum metabolism markers for triple-negative breast cancer. The method includes respectively carrying out metabonomics analysis on serum samples of experimental groups A and control groups B by the aid of LC / MS (liquid chromatography / mass spectrometry) instruments; carrying out model discriminant analysis on response intensity data of peaks of substances in the samples; respectively carrying out PCA (principal component analysis) on the experimental groups A and the control groups B; building PLS-DA (partial least square- discriminant analysis) and OPLS-DA (orthogonal partial least square-discriminant analysis) models on the basis so as to obtain difference expression metabolites; screening and identifying the biological markers related to breast cancer carcinogenesis and metastasis. The biological markers include hemolytic lecithin, sphingomyelin and small-molecule amino acid. The method has the advantages that results obtained by the aid of the method have an important significance on illustrating change rules of contents of characteristic metabolites in the serum of patients who suffer from the triple-negative breast cancer and illustrating effects of the metabolites in tumor formation and development procedures; effective breast cancer early diagnosis target sites can be acquired by the aid of the method, and data bases can be provided for establishing specific cancer diagnosis models.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

The invention belongs to the technical field of medicine and discloses a preparation method of an oxygen bridge dicycloheptene compound containing a resveratrol group. One of a 3-(4-hydroxyphenyl)-4-(((E)-3, 5-dihydroxystyryl)phenyl)furan compound and a 3, 4-bis(4-hydroxy-phenyl)furan compound and one of a vinylsulfonate and a vinylsulfonate derivative as raw materials undergo a reaction without a catalyst at 90 DEG C for 8h to produce the oxygen bridge dicycloheptene compound containing a resveratrol group. The oxygen bridge dicycloheptene compound has an action method different from that of the existing anti-breast cancer drug tamoxifen. The oxygen bridge dicycloheptene compound can effectively inhibit growth of breast cancer cells MCF-7 and triple-negative breast cancer cells MDA-MB-231, has good anti-inflammatory activity and has an application prospect in breast cancer treatment.

The invention discloses a benzimidazole-containing Tr*ger's base type compound as well as a preparation method and application thereof. A structural formula of the compound is shown as a formula 3; the compound is prepared by carrying out aldimine condensation reaction on 2,8-dialdehyde-Tr*ger's base and substituted o-phenylenediamine. An in-vivo experiment shows that the benzimidazole-containingTr*ger's base type compound has relatively high inhibition activity on non-small cell lung cancer cells (A549), triple-negative breast cancer cells (231) and triple-positive breast cancer cells (MCF-7), and has low toxicity in human normal cells; the benzimidazole-containing Tr*ger's base type compound can be mixed with human body acceptable acid-forming salt or a medical carrier to form an anti-tumor drug. The invention provides a candidate compound for researching and developing a novel drug for treating triple-negative and triple-positive breast cancer and non-small cell lung cancer. The formula 3 is shown in the description.

The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.

Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

The invention belongs to the technical field of medicine, and particularly relates to an application of a compound separated and extracted from burdock to serving as an STAT3 inhibitor. The compound I can be used for a medicine composition for treating triple negative breast cancer. The compound I and docetaxel are combined into a compound preparation for treating triple negative breast cancer for use. Phosphorylation of STAT3 is remarkably inhibited through burdock aglycone in a cell and animal tumor-bearing model, and the burdock aglycone is free of obvious toxic and side effects on other normal tissues. The application has the advantages of being proper in dosage, remarkable in curative effect, clear in action target, small in toxic and side effect and the like, and has the broad anticancer application prospect in clinic. The compound preparation has the low toxic and side effects. As the toxicity of the burdock aglycone is quite low, and the burdock aglycone and the docetaxel are used as a composition, under the condition that the same anticancer curative effect is achieved, the dosage of the docetaxel can be remarkably decreased, and therefore the toxic and side effects brought by the docetaxel can be further reduced.

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

The invention relates to a triple negative breast cancer marker COL4A2 and application thereof. By means of comparison researches on different cell lines, a specifically expressed gene COL4A2 is discovered in the triple negative breast cancer cell line MDA-MB-231, the sequence interfering with expression of the COL4A2 gene is further designed and synthesized and is respectively constructed to plasmid vectors to transfect the cell MDA-MB-231, and a sequence capable of efficiently interfering with expression of the COL4A2 gene is successfully obtained. The triple negative breast cancer marker COL4A2 and the siRNA efficiently interfering with the marker gene have an important clinical application value.

The invention provides a furanocoumarin-Base derivative, wherein the structural formula of the derivative is as shown in the following formula 6 or 7; the derivative is synthesized by performing ringformation and coupling reaction on parabromoaniline,paraformaldehyde, 4-hydroxycoumarin, isonitrile and n-butyllithium; and the synthesis process is mild in reaction condition, short in reaction timeand high in yield. The Base derivative containing a coumarin fragment has excellent luminescent property and high bioactivity; some of the products have anti-tumor activity, show high-selectivity inhibition on human triple negative breast cancer cells (MDA-MB-231) and have research value of being further developed into anti-tumor medicines; and the other products can be applied to synchronous detection on neuroblastoma metabolites homovanillic acid (HVA) and vanilmandelic acid (VMA) and have the potential of being developed into a high-efficiency fluorescent probe for human neuroblastoma earlywarning and definite diagnosis.

The invention discloses a marker used for in-vivo tracing and manual removal of CAR-T cells. The marker comprises a trace-linker 1 with a sequence as shown in SEQ ID No. 18, a trace-linker 2 with a sequence as shown in SEQ ID No. 19 and a trace-linker 3 with a sequence as shown in SEQ ID No. 19. The invention also discloses a CAR-T therapy vector including the marker and a construction method thereof. Moreover, the invention further discloses application of the marker to preparation of the CAR-T therapy vector and drugs used for treating triple-negative breast cancer. The marker provided by the invention can realize controllable in-vivo tracing, in-vitro separation and manual removal of CAR-T cells without influence on the tumor killing effect of the CAR-T cells, so the security of CAR-T cell therapy is greatly improved, and a powerful pool can be provided for deeper analysis of the process of CAR-T cell therapy. The vector provided by the invention can express a targeting chimeric antigen receptor of CD117 in human T lymphocytes, guides and activates killing effect of T lymphocytes on CD117 positive cells, and is applicable to treatment of triple-negative breast cancer in clinical practice.

The invention relates to the technical field of breast cancer diagnosis, and specifically discloses RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer. The application of the RNA circEPSTI1 in the triple negative breast cancer comprises the following steps: firstly, collecting a to-be-detected suspected triple negative breast cancer tissue sample, extracting total RNA, specifically and reversely transcribing the cyclic RNA circEPSTI1 (hsa_circRNA_000479) into cDNA (Complementary Deoxyribonucleic Acid) by using the total RNA as a template; carrying out real-time quantitative PCR (Polymerase Chain Reaction) amplification by using a specific PCR primer; using beta-actin as a reference gene, thus obtaining a relative quantitative deltaCT value of circEPSTI1; reminding that the circEPSTI1 is in positive expression when deltaCT is smaller than or equal to 5.52. According to the RNA circEPSTI1 and the application thereof in the triple negative breast cancer, disclosed by the invention, the RNA circEPSTI1 is applied to prognostic prediction of a triple negative breast cancer patient through relatively and quantitatively detecting the expression situation of the circEPSTI1 in the suspected triple negative breast cancer tissue sample.